05B4 Mastrangelo, Michael J. - Thomas Jefferson University - Thomas Jefferson University
Dr. Mastrangelo

Michael J. Mastrangelo, MD

Contact Dr. Mastrangelo

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Intralesional therapy for in-transit and satellite metastases in melanoma
  2. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases
  3. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
  4. Altered drainage patterns in patients with melanoma and previous axillary dissection
  5. A pilot study of sunitinib malate in patients with metastatic uveal melanoma
  6. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
  7. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma
  8. Defining the critical hurdles in cancer immunotherapy
  9. Masthead
  10. Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy
  11. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine
  12. In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2
  13. Conjunctival melanoma: Bladder and upper urinary tract metastases
  14. The wrath of RAFs: Rogue behavior of B-RAF kinase inhibitors
  15. Malignant melanoma presenting as obstructive jaundice secondary to metastasis to the ampulla of vater
  16. The Role of Anti-Tumor Necrosis Factor Receptor Agents in Cancer Survivors: Does the Risk Justify the Benefit?
  17. Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: Immunoadhesins for human IL-10 with therapeutic potential
  18. High-dose immunoembolization: Survival benefit in patients with hepatic metastases from uveal melanoma
  19. Impact of malignant disease on young adults.
  20. Foreword
0